Colorectal LLM Wiki

Browse
Home / Conditions / Anal Intraepithelial Neoplasia
Condition created 2026-08-24 · updated 2026-08-24
colorectalanal-intraepithelial-neoplasiaAINHPVdysplasiaprecancerhivhigh-resolution-anoscopytextbookreferenceASCRS

Anal Intraepithelial Neoplasia

Ninth and final chapter of Part II ("Anorectal Disease") — Part III ("Malignant Disease") begins with ASCRS Ch20 immediately after. Anal intraepithelial neoplasia (AIN) is the dysplastic growth of squamous epithelial cells at the anal transition zone (see Colorectal Anatomy & Embryology for the underlying anatomy — this page closes that page's previously-flagged forward reference), considered a premalignant stage of anal cancer. Its histologic/cellular findings mirror cervical dysplasia, and cells of the anal and cervical canals share embryologic, cytologic, and histopathologic characteristics.

Nomenclature

The Lower Anogenital Squamous Terminology (LAST) Standardization project established a unified two-tiered nomenclature for HPV-associated lesions: low-grade squamous intraepithelial lesion (LSIL) and high-grade squamous intraepithelial lesion (HSIL). In the anal canal, LSIL correlates with AIN-1 or anal condyloma (very mild to mild dysplasia); HSIL correlates with AIN-2 (moderate dysplasia) and AIN-3 (severe dysplasia). Cytologically, abnormal squamous cells are classified as: (a) atypical squamous cells of undetermined significance (ASCUS); (b) atypical squamous cells, cannot rule out high-grade squamous intraepithelial lesion; (c) LSIL; (d) HSIL. Invasive cancer likely arises from one or more foci of HSIL.

Epidemiology

AIN develops from HPV contact, generally through direct exposure. Nearly all sexually active men and women acquire at least one HPV type in their lifetime (79 million currently infected in the US, equal prevalence in developed/developing world). ~90% of immunocompetent infected patients remain asymptomatic, and most infections resolve without treatment within 2 years — disease progression and condyloma/neoplasia presence are likely related to immune status. HPV infection is mainly subclinical but can present as grossly apparent (condyloma), microscopically apparent, or latent (clinically silent for months to years post-exposure, with potential to migrate from the genitalia to the anus).

Risk factors for HPV infection: uncircumcised men, number of sex partners (directly proportional), sex with a partner who has had many sex partners, sex with uncircumcised men, and early age at first sexual contact. >150 HPV serotypes exist; high-risk types 16, 18, 31, 33, 35, and 45 produce E6 and E7 proteins that inhibit the p53 and Rb tumor suppressor proteins. Types 6 and 11 cause 90% of genital warts (see Anorectal Sexually Transmitted Infections for the fuller genital-warts content), while 79% of anal squamous cell carcinoma is attributable to type 16 or 18. With the 2006 HPV vaccine introduction, prevalence of HPV types 6/11/16/18 (by cytology) dropped

50% among teens/young women, and genital wart cases have decreased since 2011 (71% prevalence decrease among 14–19-year-olds, 61% among 20–24-year-olds by 2017 data) — presumably reflecting increased vaccination.

Incidence of AIN in the general population is difficult to estimate: LSIL may regress or progress to HSIL, while HSIL typically does not regress (though this may be influenced by underlying immune status). Anal cancer rates are low (~1.8 cases per 100,000), but epidemiologic studies show increasing rates of high-grade AIN and anal cancer in both sexes (~2% average annual rise in new anal cancer cases over the last decade), probably reflecting higher screening rates. Most AIN reports are retrospective and heavily biased by heterogeneous immune-status populations — AIN (I–III) has been reported in 6–22% of women with genital (cervical, vaginal, and/or vulvar) intraepithelial dysplasia. Rate of conversion to anal cancer is controversial: prospective studies suggest a rate similar to cervical cancer (9–13% AIN-3-to-cancer conversion within 5 years for untreated patients), but a large 2012 meta-analysis found much lower progression rates (1 in 600/year for HIV+ MSM, 1 in 4000/year for HIV− MSM) — the discrepancy may reflect the mixed AIN-2/AIN-3 population within that meta-analysis.

Screening and surveillance

Most at-risk patients undergo screening with digital rectal exam, anal cytology, and anoscopy. Anal cytology: an unlubricated, moistened Dacron swab inserted ~3–4cm into the anus, removed with a circular motion, preserved in liquid medium (preferred over fixative slide prep — avoids fecal material/bacteria/air-drying artifact and allows ancillary studies). Bowel prep is unnecessary; cytology must precede any instrumentation/lubrication, followed by digital rectal exam and anoscopy. Graded with the same classification as gynecologic samples: insufficient, normal, ASCUS, LSIL, HSIL, or anal cancer.

Cytology sensitivity/specificity are difficult to interpret (69–93% / 32–59%); false-negative rates differ by risk factor (MSM 23% in HIV− vs. 45% in HIV+). One study of 1185 patients undergoing anal cytology found unsatisfactory-cytology cases with SIL on biopsy showed LSIL in 19%, ASCUS had an 84% rate of biopsy-proven disease, and sensitivity was higher (92%) for high-grade AIN or worse (AIN2+). Another retrospective study (327 anal cytology results, 182 patients with dysplasia — 75% low-grade, 25% high-grade): 75% of dysplastic cytology were followed by clinical exam within 1 year, 50% were biopsied; probability of histologic dysplasia after cytologic dysplasia was 72%, and 28% of low-grade cytology results were upgraded to advanced disease (high-grade or invasive cancer) on histology. Any abnormal cytology raises the possibility of a high-grade lesion, and cytology may not correlate with histology — patients with high-grade cytology but negative anoscopy/pathology should be followed closely. The ANCHOR trial (Anal Cancer HSIL Outcomes Research) aims to determine whether treating precancerous HSIL vs. active surveillance reduces anal cancer incidence in HIV-infected individuals (results not yet available at time of writing).

Risk is highest in immunosuppressed individuals (difficulty clearing HPV); rates of anal dysplasia in all HIV+ patients are substantial regardless of sexual practices — a value for screening in this group generally — though highest risk is specifically in HIV+ MSM. Screening populations should also include organ transplant patients, women with a past history of cervical/vulvar/perineal dysplasia, and patients with medically-induced immunosuppressive conditions. Past STI history may also represent an important screening population, though it's unclear whether prior condyloma indicates a tendency toward benign warts specifically vs. cancer risk, and difficult to prove synergy between HPV and other STIs (syphilis, gonococci, HSV) speeding transformation to AIN.

The value of anal cancer screening is difficult to quantify. Screening HIV+ homosexual/bisexual men for anal dysplasia offers quality-adjusted life expectancy benefits at a cost comparable with other accepted clinical preventive interventions; cost per HSIL found has been estimated at $809.39. A prospective screening study of 284 high-risk MSM using all 3 HPV-testing/cytology/HRA modalities found only 15% of the cohort tested negative for HPV (a methodologic weakness); cytology missed nearly one-third of high-risk lesions, suggesting HRA has the most clinical screening use. HRA's effectiveness at preventing dysplasia progression or cancer development has only been evaluated in retrospective cohort studies. A retrospective review of 246 patients treated with HRA-targeted HSIL/LSIL destruction over 10 years found recurrent HSIL in 57% of patients at a 19-month average follow-up, but only 1.2% progressed to invasive cancer despite treatment.

Progression

Much of what is known about AIN-to-SCC transformation is extracted from the cervical cancer literature. Genetic changes proposed to occur after viral integration include chromosomal abnormalities (1, 3, 7, 8, 11, 15, and 20 all reported); a gain in the long arm of chromosome 3q is one of the most frequently reported changes (also seen in the transition from low-grade to severe cervical dysplasia/cervical cancer). Following viral genome incorporation into host DNA, cellular changes/atypia correspond to AIN I, which can progress to AIN II and III and ultimately dedifferentiate into squamous cell cancer. It is unclear whether AIN development must traverse all these steps or if SCC can skip one or more phases. The oncogenetic pathway is similar to that described in cervical cancer.

Once AIN is established, dysplasia rarely regresses; however, persistence data is incomplete since many patients don't follow up for surveillance. It's also unclear why anal dysplasia is thought more persistent than equivalent cervical dysplasia despite a common pathogenic pathway — ~60% of low-grade cervical lesions spontaneously regress. Small limited-follow-up reports show higher progression rates to anal cancer, especially in immunosuppressed patients: Scholefield et al. followed 35 AIN-III patients (74% women, median 63 months, all HIV-negative, six on long-term systemic immunosuppressants) — 3 (8.5%) progressed to invasive anal SCC, all of whom were on long-term immunosuppressants. Watson et al. followed 72 AIN I-III patients (72% women, median 60 months, 94% prior genital malignancy, 7% HIV+, 23% on chronic immunosuppression) — 15% had histologic progression (AIN II→III or AIN III→SCC), and 11% developed anal SCC.

Diagnosis

AIN is typically asymptomatic but may cause pruritus, bleeding, discharge, irritation, tenesmus, and pain (see Pruritus Ani for that page's differential, which already flagged Bowen's disease/Paget disease/cloacogenic carcinoma as refractory-pruritus causes requiring biopsy exclusion — this chapter supplies the fuller AIN-specific content behind that flag). Direct anal examination and detailed digital rectal exam are important; thorough history/physical exam should emphasize other HPV-related diseases (oral cancer, gynecologic dysplasia) and other genital lesions, with head-to-toe evaluation for squamous cell lesions considering all lymph node basins; gynecology/urology referral considered individually.

Diagnosis is made from cytology or biopsy. Digital rectal exam and anoscopy sensitivity is fairly low for AIN detection, though anoscopy may identify macroscopic AIN areas (often appearing as benign condylomata but may return with AIN on biopsy). If screening is positive for HSIL/LSIL, refer to a surgeon experienced with these lesions for formal biopsy. Cytology sensitivity/specificity for any-grade AIN detection vary significantly (47–90% / 32–60%). Formal biopsy (via conventional anoscopy or HRA) provides sufficient tissue for microscopic LSIL/HSIL determination — a more definitive diagnosis than cytology alone.

High-resolution anoscopy (HRA): office-based tool analogous to gynecologic colposcopy, used to diagnose and treat AIN. Typically performed in left/right lateral position, no bowel prep necessary, usually without analgesia. After 3–5% acetic acid application for 2–5 minutes, a magnifying anoscope examines the anus/lower rectum — acetic acid makes dysplastic cells more visible vs. surrounding tissue. Iodine-based Lugol's solution may also detect dysplastic tissue (only healthy epithelium absorbs it, appearing wood-like; dysplastic tissue doesn't absorb it, appearing yellowish) — though the chapter authors' own protocol avoids Lugol's (interferes with proper AIN I vs. AIN II/III differentiation) and relies on acetowhitening alone. Entire anal canal and anal verge should be examined, emphasizing the transition zone. Dysplastic epithelium appears scaly white with greater disarray of vascular patterns and tissue friability as dysplasia grade increases. The microscopic appearance of variable-grade AIN has also been described as similar to that of the cervix.

The impact of HRA was recently evaluated in a cohort of 727 MSM who underwent ablation of all HRA-identified lesions (median 2.2-year follow-up): recurrence at 1 year was 53% in HIV+ patients and 49% in HIV− patients; over follow-up, 5 patients developed cancer (probability 1.9% at 3 years). A retrospective review of 424 patients comparing HRA vs. expectant management in 2 cohorts found anal cancer occurred in one HRA patient and two expectant-management patients, with similar 5-year progression rates between cohorts.

Treatment

Progression of AIN to SCC is relatively rare; determining which patients benefit from treatment and with what modality requires expertise — patients with positive anal cytology or biopsy-proven AIN should be referred to expert centers given significant variability in management/surveillance guidelines even among specialists. Management spectrum: observation, topical therapies, local ablations, and surgical excision — recommendations are mostly based on single-institution case-control series rather than large RCTs. Goal: reduce progression to anal cancer while decreasing morbidity and preserving function.

Common treatment options (advantages/disadvantages/cure/recurrence, per the chapter's summary table):

  • Observation — low cost, no side effects; poor cure rate, time-consuming.
  • Imiquimod — minimal pain, easy to use; poor cure rate, burning, moderate cost, high recurrence after stopping.
  • 5-FU — easy to use; poor cure rate, burning, moderate cost, high recurrence after stopping.
  • Infrared coagulation (IRC) — clinic-based; requires special equipment; good cure, moderate recurrence in immunosuppressed patients.
  • Ablation (electrocautery) — single use; painful, costly; good cure, moderate recurrence in immunosuppressed patients.
  • Wide local excision — removes all tissue; painful, requires OR, cosmetic/functional issues; good cure, low recurrence.

Expectant management

Conservative strategy advocated for select AIN patients: low-grade dysplasia typically undergoes observation with close clinical follow-up every 4–6 months. A more intense program (cytology, HRA, targeted biopsies) demonstrated a 78% clearance rate with 1.2% progression to invasive SCC over 10 years. A recent large retrospective review comparing HRA vs. expectant management found no progression difference as long as patients were compliant with frequent follow-up. Based on AIN's relatively low progression/malignant-potential rate and the increased adverse-effect/morbidity rates of topical/ablative/surgical treatments.

Topical therapies

  • Trichloroacetic acid (TCA) — generally well tolerated, no reported systemic side effects, efficacious after only a few applications; doesn't require patient adherence (provider-applied). One study: 79% resolution/downgrading to LSIL at 3–6 months post-treatment (single treatment improved/resolved 49% of lesions, two treatments 28%; 21% recurrence). Another study: 72% of lesions resolved/downgraded to LSIL in 54 men with HSIL (fewer-than-3-lesion patients had greater clearance).
  • 5-Fluorouracil (5-FU) — two retrospective studies reported 55–57% response rates. One study of 46 HIV-positive LSIL/HSIL patients: 39% complete response, but 50% recurrence at 6 months among complete responders. 73–85% of patients report adverse effects (anal pain, irritation, hypopigmentation), but only 1–2 patients per study discontinued treatment.
  • Cidofovir — one prospective pilot study (16 HIV+ HSIL patients, topical 1% cidofovir 3×/week ×4 weeks): 63% complete response at 12 weeks, but 20% recurred by 24 weeks. A single-arm trial (33 HIV+ perianal-HSIL patients, self-applied gel in 2-week cycles ×6 cycles, 79% completion): 51% response (15% complete, 36% partial); 2 patients progressed during treatment. Requires compounding pharmacy preparation and may not be covered by standard insurance, limiting potential use.
  • Imiquimod — most-tested topical agent, examined in two RCTs and one prospective cohort study. A double-blinded placebo-controlled RCT (64 HIV+ MSM, 5% imiquimod 3×/week ×4 months): superior response with imiquimod (43% vs. 4%) among the 53 completers; 61% of imiquimod responders had sustained response at 36 months. A prospective study (44 histologically-proven perianal/intra-anal HSIL patients, 5 days/week self-administered 5% imiquimod): 45% complete/partial response at 16 weeks; non-responders given an additional 16 weeks, reaching 66% total response rate. Topical therapies generally are relatively efficacious with few severe side effects for LSIL/HSIL — most common is a localized skin reaction (erythema, itching, burning); few patients discontinue for intolerable side effects, and bothersome side effects typically respond to topical analgesics/warm baths/dose modification. A substantial number of responders recur once treatment stops — consider using topicals in patients who can't undergo ablative therapy, or in conjunction with ablative therapy.

Local ablative therapies

Targeted destruction of dysplastic lesions (fulguration with electrocautery, excision, or infrared coagulation/IRC) in conjunction with HRA or anoscopy — effective at achieving high complete-response rates particularly in immunocompetent patients. Often OR-based but increasingly clinic-based with local anesthesia; ablation is typically targeted to areas with dysplasia evidence with no margin requirement, as disease is limited to the epidermis (deeper dermal tissue destruction unnecessary).

  • Electrocautery — response rates initially as high as 75–80%, but recurrence common. An observational study of 83 HIV+ MSM with HSIL: 33% complete response, 34% partial response, with increased success in patients undergoing multiple sessions; recurrence 25% at a median 30-month follow-up.
  • Infrared coagulation (IRC) — short-term efficacy demonstrated in a retrospective study of 74 HIV+ MSM with HSIL: 64% had complete or partial response. Long-term follow-up (96 MSM with HSIL treated with IRC): resolution in 82% HIV+ and 90% HIV-negative; after 1 year from first treatment, recurrence (mainly metachronous) in 38% HIV-negative and 61% HIV+ MSM respectively. IRC advantage: less pain, often clinic-based.

In general, local ablative therapies are associated with minimal morbidity and reasonably well tolerated. Often multiple sessions are required and recurrence remains common. Care should be taken to avoid large field defects, scarring, or stricture formation, with the goal of preserving healthy tissue given patients will often need further surveillance/intervention.

Wide local excision

Historically the mainstay of AIN treatment via mapping biopsies + wide local excision; this often removed large amounts of healthy/uninvolved tissue along with dysplastic lesions. 9–63% of patients developed recurrences, with repeated procedures resulting in long-term complications including anal stenosis and fecal incontinence, particularly in patients with circumferential lesions or significant disease burden. With alternative techniques now available, mapping with wide local excision is not recommended even for diffuse disease.

Treatment summary

Few studies compare different treatment modalities. One study randomized 148 HIV+ MSM with SIL (57% HSIL) to 4 months of 5-FU, 5% imiquimod, or monthly electrocautery: complete response (post-treatment biopsy) 17%/24%/39% respectively; partial/complete response in the HSIL group 43%/46%/68% respectively; side effects 27%/43%/18% respectively; at 72 weeks post-treatment, recurrence rates 58%/71%/68% respectively. Due to the lack of high-quality RCTs comparing strategies, guideline development remains difficult; treatment decisions should be based on patient goals, immunosuppression/ dysplasia history, comorbidities, and underlying bowel function (per the chapter's treatment algorithm):

  • AIN I: high-risk/PMHx of CIN-AIN/immunosuppressed patients get HRA every 6–12 months plus annual cytology; immunocompetent patients get annual cytology + anoscopy OR annual HRA (if HRA normal for 2 consecutive years, step down to annual cytology alone).
  • AIN II/III: ablation, then differ by immune status — immunocompetent patients get HRA every 3–6 months with annual cytology; immunosuppressed patients get HRA every 3–4 months with annual cytology; if recurrent or too extensive for ablation, consider topical therapy plus HRA every 3 months. If disease becomes normal or AIN I, step down to the AIN I pathway.

For LSIL patients who will be compliant with surveillance, expectant management with or without HRA addition may be the best strategy. For immunocompetent HSIL patients, targeted surgical ablation guided by HRA is the most effective/generally well-tolerated eradication approach. Defining which modality to employ in immunocompromised SIL patients is more difficult — this population presumably has a higher likelihood of LSIL-to-HSIL/SCC progression favoring more aggressive intervention, but also has increased recurrence rates necessitating repeated treatments (risking increased scarring/ stenosis). Best approach for this population is likely a combination of close observation and topical therapy vs. ablative treatments, depending on disease extent/severity.

Surveillance/prevention

AIN recurrence rate is high after all treatment modalities, making surveillance necessary — though no definitive data/guidelines exist on optimal surveillance strategy. In a large retrospective review (424 enrolled patients with biopsy-proven AIN followed after ablative/topical therapy with annual DRE/cytology — 220 underwent regular HRA, 204 underwent HRA only if DRE/cytology was positive): no significant 5-year anal-SCC-rate difference between groups; in both groups, patients who progressed to anal SCC were less compliant with surveillance. The authors concluded patient compliance, not a particular surveillance program, was the key factor in reducing progression/recurrence.

HPV vaccination shows increasing evidence of AIN-incidence reduction. A large RCT (>4000 boys/men, placebo-controlled, double-blinded) demonstrated quadrivalent HPV vaccine efficacy preventing external genital lesions in patients without prior HPV evidence (Giuliano et al.). A subset analysis of 602 MSM found vaccine efficacy for preventing AIN (grades 2/3) associated with HPV 6/11/16/18: 50.3% intention-to-treat, 77.5% per-protocol efficacy population; efficacy for preventing AIN associated with any HPV type was 25.7%/54.9% (ITT/per-protocol) respectively. A trial specifically evaluating quadrivalent HPV vaccine efficacy for AIN prevention in HIV+ MSM ("Vaccine Therapy in Preventing HPV Infection in Young HIV-Positive Male Patients Who Have Sex with Males") is completed with results pending. It's postulated that vaccinating girls/boys prior to sexual-activity onset may reduce AIN incidence, prevent AIN 2/3 recurrence, and halt progression to anal SCC — but more robust data is needed.

Conclusion

AIN is a precursor to anal squamous cell cancer. The actual rate of AIN-to-SCC progression is unknown, but detection/treatment of dysplastic lesions likely decreases progression risk. Risk factors for AIN development/progression: HPV infection (particularly high-risk strains), HIV positivity, MSM, and transplant patients. Treatment modalities include expectant management, topical agents, local ablation, and surgical excision, individualized based on patient/disease factors. Regardless of treatment approach, recurrence is common, so ongoing surveillance is recommended for all patients with AIN history, and patient compliance is critical. Future goals: improve prevention/early-lesion detection and develop consensus guidelines for nomenclature, treatment, and surveillance.

  • Colorectal Anatomy & Embryology — the anal transition zone/HPV-dysplasia anatomy this page's content builds directly on; closes that page's previously-flagged Ch19 forward reference.
  • Anorectal Sexually Transmitted Infections — HPV epidemiology, high-risk subtype (16/18) detail, genital warts/HIV-anorectal-disease content this page builds on; HRA screening recommendation for high-risk MSM/HIV-positive patients already flagged on that page.
  • Pruritus Ani — AIN-related lesions (Bowen's disease, Paget disease, cloacogenic carcinoma) already flagged on that page as refractory-pruritus differentials requiring biopsy exclusion; this page provides the fuller dysplasia-specific content.
  • Anal Cancer — AIN is anal squamous cell carcinoma's histologically confirmed precursor lesion; that page's epidemiology/risk-factor section builds directly on this page's HPV biology.

Open items / gaps

  • No primary-literature source yet for the cited trial data (Giuliano quadrivalent-HPV-vaccine RCT, imiquimod/cidofovir/5-FU response-rate studies, Scholefield and Watson AIN-progression cohorts) — known only via this textbook chapter's synthesis.
  • The ANCHOR trial (treating HSIL vs. active surveillance in HIV-infected individuals) is explicitly noted as not yet reporting results at the time of this chapter's writing — worth a follow-up ingest once published, as it directly bears on this page's core clinical question (does treating AIN actually reduce anal cancer incidence).
  • Rate of AIN-to-SCC conversion is explicitly flagged as controversial (9–13%/5yr in some prospective studies vs. 1-in-600-to-4000/yr in a large meta-analysis) — not reconciled here, reported as the chapter presents it.